Alpha Cognition (Alpha Cognition) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Change In Receivables?

Alpha Cognition's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Alpha Cognition's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Alpha Cognition's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Alpha Cognition's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Alpha Cognition's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alpha Cognition's liquidation value for the three months ended in Mar. 2024 was $-1.04 Mil.

Alpha Cognition Change In Receivables Historical Data

The historical data trend for Alpha Cognition's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Change In Receivables Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

0.01

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial										-	-	-	-	-

Alpha Cognition Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Alpha Cognition (OTCPK:ACOGF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alpha Cognition's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Alpha Cognition's accounts receivable are only considered to be worth 75% of book value:

Alpha Cognition's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.259	-	3.296	+	0.75 * 0	+	0.5 * 0
=	-1.04

Alpha Cognition Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (Alpha Cognition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ACOG:Canada

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.